News >

FDA Eliminates REMS Requirement for ESAs

Silas Inman @silasinman
Published: Friday, Apr 14, 2017

The FDA has eliminated the need for risk evaluation and mitigation strategy (REMS) certification prior to the administration of erythropoiesis-stimulating agents (ESAs) for anemia due to myelosuppressive chemotherapy. The decision applied specifically to the agents epoetin alfa (Epogen/Procrit) and darbepoetin alfa (Aranesp).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Cancer Summaries and Commentaries™: Report from San Diego on Advances in the Treatment of GvHDDec 30, 20191.5
Publication Bottom Border
Border Publication
x